Verified Nov 2026
Batteries & E-Mobility
·

Root, Lucerne
·
Since 2000
Novocure is a global oncology medical device company founded in 2000 that develops and commercializes Tumor Treating Fields therapy, a non-invasive platform using alternating electric fields to disrupt cancer cell division. Headquartered in Saint Helier, Jersey, with over 1,300 employees and revenues in the $500 million to $1 billion band, the company serves patients with aggressive solid tumors across North America, Europe, the Middle East, and Asia. Its marketed products include Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with recent expansion into pancreatic cancer treatment.
Novocure at a glance
Revenue
$500M-1B
Est. band
Employees
1,000-5,000
Founded
2000
Headquarters
Root, Lucerne
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Novocure is a global oncology medical device company founded in 2000 that develops and commercializes Tumor Treating Fields therapy, a non-invasive platform using alternating electric fields to disrupt cancer cell division. Headquartered in Saint Helier, Jersey, with over 1,300 employees and revenues in the $500 million to $1 billion band, the company serves patients with aggressive solid tumors across North America, Europe, the Middle East, and Asia. Its marketed products include Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with recent expansion into pancreatic cancer treatment.
At a glance
Attribute | Detail |
|---|---|
Founded | 2000 |
Headquarters | Root, Lucerne |
Employees | 1,000-5,000 |
Revenue | $500M-1B (estimated) |
Primary capability | Batteries & E-Mobility |
What Novocure makes
Novocure offers two primary commercialized products, Optune Gio and Optune Lua, both designed for use alongside standard chemotherapy or other therapies in defined cancer indications.
Latest developments
2026-11-09 — Press Releases | Novocure GmbH (novocure.com)
2026-10-29 — Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance | Thu, 10/29/2026 - 07:00 (novocure.com)
2026-10-28 — Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement | Wed, 10/28/2026 - 07:00 (novocure.com)
2026-10-01 — Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer | Thu, 10/01/2026 - 09:00 (novocure.com)
2026-09-14 — Novocure at Morgan Stanley conference: growth, discipline and expansion By Investing.com (investing.com)
2026-08-13 — Tumour Treating Fields (TTFields) support | Sciensus and Novocure (sciensus.com)
Company details
The company operates as a private entity with over 1,300 employees and serves medical oncology and thoracic oncology sectors across multiple geographic regions. Novocure was founded in 2000, has an estimated 1,000-5,000 employees, and is headquartered in Root, Lucerne.
Frequently asked questions
What does Novocure make?
Novocure is a global oncology medical device company founded in 2000 that develops and commercializes Tumor Treating Fields therapy, a non-invasive platform using alternating electric fields to disrupt cancer cell division. Headquartered in Saint Helier, Jersey, with over 1,300 employees and revenues in the $500 million to $1 billion band, the company serves patients with aggressive solid tumors across North America, Europe, the Middle East, and Asia. Its marketed products include Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with recent expansion into pancreatic cancer treatment.
Where is Novocure headquartered?
Novocure is headquartered in Root, Lucerne.
When was Novocure founded?
Novocure was founded in 2000.
How big is Novocure?
Novocure has an estimated 1,000-5,000 employees, with revenue in the $500M-1B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
